Home > Oncology > ESMO 2020 > Gynaecological Cancers > Treatment of newly diagnosed ovarian cancer

Treatment of newly diagnosed ovarian cancer

ESMO 2020
Addition of atezolizumab to standard first-line chemotherapy did not increase progression-free survival (PFS) of patients with ovarian cancer. The SOLO1 trial showed impressive 5-year follow-up data. Platinum-taxane chemotherapy in combination with bevacizumab is an established front-line regimen for ovarian cancer in advanced stage setting. Blocking tumour-associated VEGF may promote T-cell infiltration into the tumour and boost immune responses [1]. This justifies combining anti-VEGF and anti-PD-(L)1 therapy. In the randomised, phase 3 IMagyn050 trial, 1,301 newly diagnosed patients with stage III/IV ovarian cancer (75% high-grade serous) were randomised to receive standard regimen (paclitaxel, carboplatin, bevacizumab) or the same regimen plus atezolizumab (200 mg every 3 weeks) [2]. The treatment was neoadjuvant and adjuvant (post-surgery) in 25% and 75%, respectively. There was no statistically significant PFS improvement in either the ITT pop...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on